EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo

Jade Jansen iD, Stefanie Kroeze, Shirley Man, Matteo Andreini, Jan-Willem Bakker, Claudio Zamperini, Alessia Tarditi, Neeltje A Kootstra iD, Teunis B H Geijtenbeek iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.03180-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Jade Jansen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam , Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HealthHolland/Aidsfonds, HealthHolland/AMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Latency reversal and subsequent elimination of the human immunodeficiency virus-1 (HIV-1) reservoir using a combination of compounds with different mechanisms of action are considered a promising tool for HIV-1 cure. Here, we analyzed HIV-1 reservoir reduction by targeting the two host factors; inhibitor of apoptosis proteins (IAPs) and DEAD-box polypeptide 3 (DDX3) using a SMAC mimetic (SMACm) and DDX3 inhibitor (DDX3i), respectively. We observed that SMACm efficiently reactivated HIV-1 in a latency Jurkat model, which was further enhanced by DDX3 inhibition. Strikingly, this compound combination strongly decreased the proportion of latently as well as transcriptionally active infected cells in a T cell line model with a dual-reporter virus. To determine the efficacy of compounds to eradicate the HIV-1 reservoir in people living with HIV (PWH), a novel ex vivo HIV-1 reservoir reduction assay (HIVRRA) was developed. DDX3i and SMACm alone reduced the HIV-1 reservoir in peripheral blood mononuclear cells (PBMCs) from the majority of PWH, whereas notably, the SMACm/DDX3i combination reduced the HIV-1 reservoir even further with 53%–90% in all PWH analyzed, while uninfected bystander cells were not affected. Our data highlight that IAPs as well as factors involved in HIV-1 replication like DDX3 are excellent targets for HIV-1 cure strategies. We show for the first time that the combination of SMACm and DDX3i reverses viral latency and specifically eliminates the HIV-1-infected cells in vitro and ex vivo . IMPORTANCE HIV-1 continues to be a major global health challenge. Current HIV-1 treatments are effective but need lifelong adherence. An HIV-1 cure should eliminate the latent viral reservoir that persists in people living with HIV-1. Different methods have been investigated that focus on reactivation and subsequent elimination of the HIV-1 reservoir, and it is becoming clear that a combination of compounds with different mechanisms of actions might be more effective. Here, we target two host factors, inhibitor of apoptosis proteins that control apoptosis and the DEAD-box helicase DDX3, facilitating HIV mRNA transport/translation. We show that targeting of these host factors with SMAC mimetics and DDX3 inhibitors induce reversal of viral latency and eliminate HIV-1-infected cells in vitro and ex vivo .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHumansNF-kappa BCD4-Positive T-LymphocytesGene Expression RegulationVirus Latency

Stichwörter der Autor:innen

DDX3HIV-1 reservoirIAPSMAC mimeticshuman immunodeficiency viruslatency reversal

Substanzen

NF-kappa B

Autor:innen und Institutionen

  • Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam , Amsterdam, the Netherlands.
  • Amsterdam Institute for Infection and Immunity , Amsterdam, the Netherlands.
  • First Health Pharmaceuticals B.V , Amsterdam, the Netherlands.

ORCID-Profile: Jade Jansen, Neeltje A Kootstra, Teunis B H Geijtenbeek

Förderung

  • HealthHolland/Aidsfonds
  • HealthHolland/AMC

Zitieren

APA

Jansen, J., Kroeze, S., Man, S., Andreini, M., Bakker, J. W., Zamperini, C., Tarditi, A., Kootstra, N. A., & Geijtenbeek, T. B. H. (2024). Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03180-23

Vancouver

Jansen J, Kroeze S, Man S, Andreini M, Bakker JW, Zamperini C, et al. Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo. Microbiology Spectrum. 2024. doi:10.1128/spectrum.03180-23

BibTeX
@article{Jansen2024,
  author = {Jansen, Jade and Kroeze, Stefanie and Man, Shirley and Andreini, Matteo and Bakker, Jan-Willem and Zamperini, Claudio and Tarditi, Alessia and Kootstra, Neeltje A and Geijtenbeek, Teunis B H},
  title = {Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.03180-23}
}
Kostenlos starten →